Jason Lettman

Mr. Lettmann is a General Partner of Lightstone Ventures as well as a General Partner on the Life Science team at Morgenthaler Ventures. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of Alexo Therapeutics, Carrick Therapeutics, Cerevance, FIRE1, Promedior, Ra Pharmaceuticals (NASDAQ: RARX), Second Genome and Vapotherm. Jason also established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe. Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences, and was involved with the founding of Zyga Technologies. Jason has an MBA with distinction from the University of Michigan’s Ross School of Business and a BA with honors from the University of Iowa.